Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
102 participants
OBSERVATIONAL
2009-09-22
2018-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will also collect DNA for future analysis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genetic Determinants of Response to Neoadjuvant Cisplatin-based Chemotherapy in Urothelial Cancer
NCT01206426
Evaluation of the Effect of Genetic Polymorphisms in ERCC1 and OCT2 on the Occurrence and Severity of Cisplatin-induced Nephrotoxicity
NCT05247671
Kidney Damage in Patients Receiving Cisplatin and Ifosfamide for Solid Tumors
NCT00695032
Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma
NCT01261728
Study in Advanced Solid Tumors
NCT01099358
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
DNA will be collected both prospectively and retrospectively (from patients that have previously received cisplatin.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prospecitive Analysis
Patients currently receiving cisplatin as treatment for their cancer.
urine samples (biomarkers)
Urine samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.
blood samples (biomarkers)
blood samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.
blood sample (DNA)
Blood sample collected for DNA analysis at anytime while on-study.
Restrospective Analysis
Patients that have previously received cisplatin as treatment for their cancer.
blood sample (DNA)
Blood sample collected for DNA analysis at anytime while on-study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
urine samples (biomarkers)
Urine samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.
blood samples (biomarkers)
blood samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.
blood sample (DNA)
Blood sample collected for DNA analysis at anytime while on-study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 18 years and older.
* Ability to understand and willingness to sign a written consent document.
* Patients may be receiving cisplatin in combination with other chemotherapeutic agents.
* Patients may be receiving cisplatin in the context of another clinical trial.
* Patients that have previously received intravenous cisplatin as part of cancer chemotherapy.
* Aged 18 years and older.
* Ability to understand and willingness to sign a written consent document.
* Patients that received cisplatin in combination with other chemotherapeutic agents are eligible.
* Patients that received cisplatin in the context of a clinical trial are eligible.
Exclusion Criteria
* Patients on dialysis or other renal replacement therapy prior to starting cisplatin.
* Uncontrolled hypo- or hyperthyroidism (patients on chronic stable doses of thyroid replacement medication are eligible).
Retrospective Analysis Group
* Unable or unwilling to submit to a one-time blood draw.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
American Society of Clinical Oncology
OTHER
National Institutes of Health (NIH)
NIH
University of Chicago
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter H O'Donnell, MD
Role: PRINCIPAL_INVESTIGATOR
University of Chicago
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Chicago
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09-135-B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.